Novavax
NVAX
11.22
-0.10
-0.88%
Novavax
US · NVAX
#2865 by market cap
Listed 1970
11.22
-0.10
-0.88%
Live - 5344 symbols - heartbeat 369s ago
· 2026-10-08 08:29
Pre-market
11.12
-0.89%
After-hours
11.16
-0.53%
Overnight
11.03
-1.69%
- Market cap
- 1.85B
- P/E (TTM)i
- -8.31
- P/Bi
- -9.71
- EPSi
- 2.58
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on NVAX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.56, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +64.69% YoY
Margins
- Gross margin
- 93.50%
- Operating margin
- 49.01%
- Net margin
- 39.19%
Key ratios & quality
- Enterprise valuei
- 1.36B
- Altman Z-Scorei
- -1.56
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.29M | 18.66M | 475.60M | 1.15B | 1.98B | 983.71M | 682.16M | 1.12B |
| Gross profit | -- | -- | 22.39M | 197.58M | 696.31M | 212.61M | 479.42M | 1.05B |
| Selling & admin expenses | 34.41M | 34.42M | 145.29M | 298.36M | 488.69M | 468.95M | 337.19M | 157.48M |
| Research & development | 173.80M | 113.84M | 747.03M | 2.53B | 1.24B | 737.50M | 391.17M | 342.32M |
| Operating profit | -173.92M | -129.60M | -416.72M | -1.69B | -644.74M | -566.51M | -248.93M | 550.64M |
| Pretax profit | -184.75M | -132.69M | -418.26M | -1.71B | -653.65M | -543.03M | -176.62M | 442.17M |
| Tax | -- | 0 | 0 | 29.22M | 4.29M | 2.03M | 10.88M | 1.87M |
| Net profit | -184.75M | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M | -187.50M | 440.30M |
| Basic EPS | -10 | -6 | -7 | -23 | -8 | -5 | -1 | 3 |
| Diluted EPS | -9.99 | -5.51 | -7.27 | -23.44 | -8.42 | -5.41 | -1.23 | 2.58 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 666.66M | 239.24M | 70.45M | 147.14M | 139.51M | 56.70M |
| Gross profit | 652.54M | 223.92M | 48.95M | 125.04M | 108.82M | 42.45M |
| Selling & admin expenses | 48.09M | 43.61M | 31.66M | 34.12M | 28.78M | 26.67M |
| Research & development | 88.94M | 79.23M | 98.27M | 75.88M | 95.47M | 70.69M |
| Operating profit | 515.51M | 101.07M | -80.98M | 15.04M | -15.43M | -54.91M |
| Pretax profit | 519.85M | 107.45M | -203.04M | 17.90M | -8.51M | -51.68M |
| Tax | 1.20M | 946.00K | -657.00K | 376.00K | 985.00K | 1.71M |
| Net profit | 518.65M | 106.51M | -202.38M | 17.53M | -9.49M | -53.39M |
| Basic EPS | 3 | 1 | -1 | 0 | 0 | 0 |
| Diluted EPS | 2.93 | 0.62 | -1.25 | 0.11 | -0.06 | -0.32 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 119.28M | 97.25M | 1.25B | 2.16B | 1.70B | 1.14B | 1.13B | 978.28M |
| Cash & ST investments | 92.13M | 78.82M | 711.05M | 1.52B | 1.34B | 568.51M | 923.12M | 735.08M |
| Inventory | -- | -- | -- | 8.87M | 36.68M | 41.70M | 8.75M | 11.55M |
| Total assets | 207.98M | 172.96M | 1.58B | 2.58B | 2.26B | 1.80B | 1.56B | 1.18B |
| Total current liabilities | 45.54M | 25.80M | 579.67M | 2.39B | 2.46B | 1.64B | 1.15B | 459.95M |
| Short-term debt | -- | 1.26M | 105.86M | 130.53M | 352.08M | 5.14M | 7.01M | 2.51M |
| Long-term debt | 319.19M | 320.61M | 322.04M | 323.46M | 166.47M | 168.02M | 169.68M | 244.21M |
| Total liabilities | 375,913,000.00 | 358,974,000.00 | 955,270,000.00 | 2,928,426,000.00 | 2,892,757,000.00 | 2,514,417,000.00 | 2,184,259,000.00 | 1,304,265,000.00 |
| Total equity | -167.94M | -186.02M | 627.21M | -351.67M | -634.08M | -716.93M | -623.84M | -127.75M |
| Retained earnings | -1.30B | -1.43B | -1.87B | -3.62B | -4.28B | -4.82B | -5.01B | -4.57B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 868.03M | 919.51M | 974.59M | 978.28M | 850.82M | 771.10M |
| Cash & ST investments | 731.48M | 612.30M | 762.89M | 735.08M | 790.33M | 719.34M |
| Inventory | 10.26M | 10.24M | 13.51M | 11.55M | 11.46M | 10.01M |
| Total assets | 1.29B | 1.34B | 1.18B | 1.18B | 1.04B | 955.58M |
| Total current liabilities | 422.17M | 389.14M | 429.87M | 459.95M | 342.46M | 330.57M |
| Short-term debt | 5.48M | 5.55M | 5.04M | 2.51M | 2.11M | 4.11M |
| Long-term debt | 170.13M | 170.57M | 243.84M | 244.21M | 291.04M | 291.49M |
| Total liabilities | 1,368,635,000.00 | 1,298,924,000.00 | 1,336,561,000.00 | 1,304,265,000.00 | 1,187,924,000.00 | 1,146,282,000.00 |
| Total equity | -75.64M | 37.63M | -156.67M | -127.75M | -144.76M | -190.71M |
| Retained earnings | -4.49B | -4.38B | -4.59B | -4.57B | -4.58B | -4.63B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -184.83M | -136.62M | -42.54M | 322.95M | -415.94M | -713.97M | -87.26M | -244.64M |
| Depreciation & amortization | 8.16M | 5.68M | 4.89M | 12.66M | 29.05M | 41.23M | 48.50M | 27.61M |
| Free cash flow | -186.20M | -138.48M | -97.16M | 265.46M | -508.92M | -772.77M | -101.90M | -251.02M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 100.06M | 97.39M | 875.62M | 564.86M | 249.23M | 360.24M | 263.27M | 0 |
| Ending cash balance | 81.96M | 82.18M | 648.74M | 1.53B | 1.35B | 583.81M | 545.29M | 256.05M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -185.50M | -127.46M | 107.80M | -39.48M | -32.42M | -72.81M |
| Depreciation & amortization | 8.34M | 7.56M | 6.59M | 5.13M | 3.06M | 3.06M |
| Free cash flow | -187.10M | -127.99M | 105.79M | -41.72M | -33.69M | -73.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 278.48M | 268.98M | 283.36M | 256.05M | 232.93M | 196.04M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -189.60 | -1,265.72 | -- | -- | -- | -- |
| ROA %i | -72.38 | -69.67 | -47.65 | -83.85 | -27.21 | -26.88 | -11.17 | 32.17 |
| ROIC %i | -- | -- | -65.29 | -286.87 | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -503.27 | -645.73 | -84.76 | -147.73 | -39.64 | -95.01 | -22.95 | 41.36 |
| FCF / sales %i | -- | -- | -- | 23.16 | -- | -- | -- | -- |
| Current ratioi | 2.62 | 3.77 | 2.15 | 0.90 | 0.69 | 0.70 | 0.98 | 2.13 |
| Quick ratioi | 2.02 | 3.35 | 1.68 | 0.82 | 0.58 | 0.53 | 0.89 | 1.83 |
| Debt / assetsi | 153.47 | 186.10 | 29.57 | 17.62 | 24.34 | 12.74 | 14.77 | 21.15 |
| LT debt / equityi | -- | -- | 57.73 | -- | -- | -- | -- | -- |
| Interest coveragei | -14.16 | -9.89 | -26.62 | -80.15 | -31.88 | -36.67 | -7.80 | 20.61 |
| Revenue CAGR (3Y) %i | -1.84 | 6.72 | -10.45 | 79.28 | 340.85 | 191.82 | 51.14 | -11.10 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 36.18 | 26.80 | 23.63 | 32.17 | -7.52 | -21.62 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 42.00 | 42.13 | 35.22 | 41.36 | -10.81 | -53.99 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.06 | 2.36 | 2.27 | 2.13 | 2.48 | 2.33 |
| Quick ratioi | 1.84 | 2.16 | 1.85 | 1.83 | 2.38 | 2.23 |
| Debt / assetsi | 17.68 | 17.10 | 21.29 | 21.15 | 28.29 | 31.11 |
| LT debt / equityi | -- | 592.53 | -- | -- | -- | -- |
| Interest coveragei | 23.53 | 19.71 | 15.43 | 20.61 | -2.97 | -10.20 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
In-house early-stage research and development (R&D)100.00%
Quote time 2026-10-08 08:29:50 · For reference only, not investment advice and not tailored to your situation.